Comparative Pharmacology
Head-to-head clinical analysis: DEXAMPEX versus METADATE ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXAMPEX versus METADATE ER.
DEXAMPEX vs METADATE ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dextroamphetamine is a central nervous system stimulant that increases extracellular dopamine and norepinephrine levels by blocking their reuptake and promoting release from presynaptic terminals.
Methylphenidate is a central nervous system stimulant that inhibits the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their concentrations in the synaptic cleft. It also acts as a weak agonist at serotonin receptors.
5-10 mg orally once daily in the morning, maximum 20 mg/day.
Initial: 10-20 mg orally once daily in the morning. May increase by 10-20 mg at weekly intervals. Maximum: 60 mg/day.
None Documented
None Documented
Terminal elimination half-life 10–13 hours in adults (7–8 hours in children). Longer in alkaline urine (up to 20 hours) due to reduced renal tubular reabsorption.
Terminal elimination half-life: 3-6 hours (mean 4.5 hours) for methylphenidate; clinical context: requires multiple daily dosing or extended-release formulation.
Renal: ~90% as unchanged drug and metabolites (primarily deaminated metabolites); fecal/biliary <2%.
Renal (80% as metabolites, <1% unchanged); fecal (10-20%) via biliary elimination.
Category C
Category C
CNS Stimulant
CNS Stimulant